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Dear editor
Obstructive sleep apnea (OSA) is associated with in-
creased risk for cardio- and cerebrovascular diseases
[1, 2]. Animal studies propose intermittent hypoxia
and the resulting inappropriate activation of sympathetic
nervous system [3, 4] as the major link between OSA and
cardio- and cerebrovascular comorbidities. However, the
OSA severity level at which continuous positive airway
pressure (CPAP) therapy offers cardio- and cerebrovascu-
lar benefit (reduction in indices of myocardial stress/in-
jury) is a matter of debate. Sub-clinical injury to the
myocardium is considered to be a precursor for the
development of incident cardiovascular disease including
heart failure [5]. Troponin T measured with a high sensi-
tivity assay (Hs-TnT) has been shown to predict incident
heart failure and cardiovascular death [6]. Further, in-
crease or decrease in Hs-TnT over time predicted in-
creased or decreased incidence of heart failure and
cardiovascular death [7, 8]. Hs-TnT has also shown to be
increased with presence and severity of OSA [9]. Stronger
correlations were reported with nadir SpO2 [10]. Roca
and colleagues, in a cohort of 1645 subjects free of coron-
ary artery disease and heart failure with a median follow
up of 12.4 years, reported that hs-TnT was associated with
risk of death or incident heart failure across various
categories of OSA after adjusting for 17 potential con-
founders [11]. Surprisingly, a recent study showed in-
creased Hs-TnT after 12 months of CPAP therapy in
patients with OSA. However, the utilization of CPAP was
not reported [12]. We report changes in Hs-TnT level as a
marker of myocardial stress/injury in a cohort of CPAP
compliant patients with OSA.
Methods
This study was approved by institutional review board of
Baylor College of Medicine and Research & Develop-
ment Committee of Michael E. DeBakey VA Medical
Center. All participants signed an informed consent
form. We enrolled adult subjects with confirmed OSA
(apnea + hypopnea index (AHI) of ≥15 obstructive and/
or mixed events/h) using attended polysomnography
(PSG). Subjects qualifying for the PSG underwent blood
sampling and completed an Epworth Sleepiness Scale
(ESS). The participants underwent attended CPAP titra-
tion and were placed on therapy. The best pressure was
the one associated with the lowest AHI while the patient
slept 20 min, or more. After titration, subjects received a
CPAP machine and related accessories (Respironics,
REMStar Pro) with card reader to monitor the compli-
ance of CPAP and were followed for 6 months. Subjects
were seen 2–3 times during the study and CPAP compli-
ance was checked during the visit. CPAP efficacy was
rechecked with overnight pulse oximetry at the end of
the study. Blood was collected in the morning between 7
and 8 AM in EDTA-containing tubes and kept at 4 °C
during processing at baseline and after 6 months of
CPAP use. Aprotinin (100 μL containing 0.6 TIU per
mL of blood) was added to one of the tubes and the
samples were then centrifuged at 3000 rpm for 30 min.
Hs-TnT concentrations were measured with a novel high
sensitivity assay, Elecsys Troponin T (Roche Diagnos-
tics®), on an automated Cobas e411 analyzer with a limit
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Results
Twenty-three subjects were enrolled and 20 subjects
completed the study. One subject died unexpectedly
at home, from unknown causes. Two subjects were
lost to follow up. Baseline and follow samples were
available for analysis in 13 and 10 subjects, respect-
ively. The subjects were all male, mean age was 59.7
(SD ± 2) years, body mass index (BMI) 36.5 (SD ± 1.8)
kg/m2. Baseline polysomnogram showed a total sleep
time of 264 min (SD ±121.9), sleep efficiency of 80 %
(SD ±10.9 %), latency to sleep onset of 14.3 min (SD
±15.77), wake after sleep onset of 48.8 min (SD ±34.7);
with stage N1 of 11 % (SD ±6.5), N2 of 70 % (SD ±14.1),
N3 of 11.8 (SD ±10.7) and REM of 11.8 (SD ±10.7). Re-
spiratory parameters at baseline were AHI of 50 (SD ± 6)
per hour of sleep, nadir SpO2 of 77 (SD ± 3), and mean
time below SpO2 of 90 % of 59.37 min (SD 98.77). Hs-
TnT at baseline was elevated and correlated with baseline
nadir SpO2 (SpO2) (Correlation Coefficient of 0.889,
p <0.001), mean time below SpO2 of 90 % (Correl-
ation of Coefficient of 0.832, p <0.001) but not with
AHI or arousal index (Fig. 1). Subjects used CPAP for
165 ± 17 days and 5.3 ± 0.35 h/night. ESS decreased
with CPAP therapy (14.6 vs 9.1, p < 0.05). Systolic and
diastolic blood pressures and heart rate remained un-
changed throughout the study period. CPAP effect-
ively reversed hypoxia in all subjects (nadir SpO2 77
± 3 % at baseline and 89.3 ± 3 post CPAP, p = 0.005)
(Table 1). Hs-TnT decreased only in subjects with
baseline nadir SpO2 of 80 % or lower (n = 4) (Fig. 2).
The absolute and percent changes in Hs-TnT com-
pared to baseline strongly correlated with baseline
SpO2 (Correlation Coefficients of 0.835 and 0.6419
respectively, both p <0.05). The absolute and percent
changes in Hs-TnT did not correlate with baseline
AHI.
Discussion
Our study, consistent with others, suggests that Hs-TnT
as a biomarker of myocardial stress/injury is elevated in
patients with OSA [11]. In contrast, the increased Hs-
TnT was associated with severity of hypoxia but not
AHI or sleep interruption as measured by arousal index.
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Fig. 1 Baseline Hs-TnT correlates strongly with baseline nadir O2 saturation. Y axis presents the nadir SpO2 during the baseline sleep study
Table 1 Sleep and metabolic parameters before and after CPAP
use
Pre and Post Treatment Data
Baseline Post-CPAP
AHI (episodes/h) 50 ± 6 -
CPAP pressure (cm H2O) - 10 ± 3.2
CPAP use (days) - 165 ± 17
CPAP use (Hrs/day) - 5.3 ± 0.35
ESS 14.6 ± 1 9.5 ± 1*
Nadir SpO2 (%) 77 ± 3 89.3 ± 3*
Mean SpO2 (%) 93.2 ± 0.7 93.8 ± 0.62
Systolic blood pressure (mmHg) 124 ± 3 129 ± 4
Diastolic blood pressure (mmHg) 76 ± 2 76 ± 2
Heart rate (bpm) 77 ± 3 72 ± 3
Body weight (Kg) 108 ± 5.3 109.6 ± 5.4*
BUN (mg/dl) 14.1 ± 1.19 14.26 ± 1.41
Creatinine (mg/dl) 0.96 ± 0.09 1.0 ± 30.06
Hs-TnT (micrograms/l) 0.012 ± 0.0085 0.011 ± 0.0035*
AHI Apnea + hypopnea index, ESS Epworth sleepiness scale, Hs-TnT Highly
sensitive troponin T
*: Significant differences compared to baseline (p ≤ 0.05) appear in bold
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the study subjects but only was associated with decline
in Hs-TnT in subjects with more severe hypoxia at base-
line. Thus, the data suggests that cardio- and cerbro-
vascular adverse outcomes related to OSA and the bene-
fits seen with CPAP therapy may greatest to those with
pronounced hypoxia as assessed by nadir Sp02 versus
other parameters used to assess sleep apnea. A major
short coming of our study is the small sample size. While
our results are provocative, they must be viewed with
caution due to the limited sample size and should be
further studied and characterized in larger studies.
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Fig. 2 Follow up versus baseline Hs-TnT: The numbers next to each data points show the nadir SpO2 at baseline
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